Stephen Stead, the British manager who runs LaborMed drug makerand who last year sealed two deals, the takeover of Ozone brandsand of a 12-product portfolio from PlantExtrakt Cluj, this yearwill focus on the company's international business, which"generates cash and profitability". "Our focus will be on thePolish market, a base for Ozone operations. It's a much more stableclimate, a large market, and we have many products undergoingregistration here. The main plus is cash. We have much betterpayment terms, compared with Romania, where the situation isdisastrous. Poland is normal from this point of view," said Stead,LaborMed CEO, in an interview with ZF. Takeovers have cementedLaborMed's position on the OTC drugs market and secured it afoothold in Poland, Bulgaria, Hungary, the Czech Republic andSlovakia. After the two deals were completed, LaborMed structuredthe company into 3 units: LaborMed (prescription drugs), Ozone (OTCdrugs) and Ozone Natural (natural products). "We expect LaborMedturnover to revolve around 70m euros this year," Stead said.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
